Abstract
It is well established that Escherichia coli represents a powerful tool for the over-expression of human proteins for structure/function studies. In many cases, such as for membrane transporters, the bacterial toxicity or the aggregation of the target protein hamper the expression limiting the application of this tool. The aim of this study was finding the appropriate conditions for the expression of reluctant proteins that is the human neutral amino acid transporters ASCT2 and B0AT1, that have great relevance to human health in cancer therapy and in COVID-19 research, respectively. The cDNAs coding for the proteins of interest were cloned in the pCOLD I vector and different E. coli strains (BL21 codon plus RIL, and RosettaGami2) were cultured in absence or in presence of glucose (0.5–1%), at low temperature (15 °C), and low inducer concentrations (10–100 µM). Cell growth and protein production were monitored by optical density measurements and western blotting assay, respectively. Even though in different conditions, the expression of both amino acid transporters was obtained.Reducing the growth rate of specific E. coli strains by lowering the temperature and the IPTG concentration, together with the addition of glucose, two reluctant human neutral amino acid transporters have been expressed in E. coli. The results have a potentially great interest in drug discovery since ASCT2 is an acknowledged target of anticancer therapy, and B0AT1 together with ACE2 is part of a receptor for the SARS-Cov-2 RBD proteins.
This is a preview of subscription content, log in via an institution to check access.
References
Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5:172
Chaudhary S, Pak JE, Pedersen BP, Bang LJ, Zhang LB, Ngaw SM, Green RG, Sharma V, Stroud RM (2011) Efficient expression screening of human membrane proteins in transiently transfected human embryonic kidney 293S cells. Methods 55(4):273–280
Miroux B, Walker JE (1996) Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J Mol Biol 260(3):289–298
Gonzalez-Montalban N, Carrio MM, Cuatrecasas S, Aris A, Villaverde A (2005) Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. J Biotechnol 118(4):406–412
Wagner S, Baars L, Ytterberg AJ, Klussmeier A, Wagner CS, Nord O, Nygren PA, van Wijk KJ, de Gier JW (2007) Consequences of membrane protein overexpression in Escherichia coli. Mol Cell Proteomics 6(9):1527–1550
Hediger MA, Clemencon B, Burrier RE, Bruford EA (2013) The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med 34(2–3):95–107
Cesar-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, Superti-Furga G (2015) A call for systematic research on solute carriers. Cell 162(3):478–487
Pochini L, Scalise M, Galluccio M, Indiveri C (2014) Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. Front Chem 2:61
Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15(4):254–266
Broer S (2009) The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition. IUBMB Life 61(6):591–599
Pochini L, Seidita A, Sensi C, Scalise M, Eberini I, Indiveri C (2014) Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modelling. Biochem Pharmacol 89(3):422–430
Cheng Q, Shah N, Broer A, Fairweather S, Jiang Y, Schmoll D, Corry B, Broer S (2017) Identification of novel inhibitors of the amino acid transporter B(0) AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes. Br J Pharmacol 174(6):468–482
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367(6485):1444–1448
Scalise M, Galluccio M, Pochini L, Console L, Barile M, Giangregorio N, Tonazzi A, Indiveri C (2017) Studying interactions of drugs with cell membrane nutrient transporters: new frontiers of proteoliposome nanotechnology. Curr Pharm Des 23(26):3871–3883
Pingitore P, Pochini L, Scalise M, Galluccio M, Hedfalk K, Indiveri C (2013) Large scale production of the active human ASCT2 (SLC1A5) transporter in Pichia pastoris—functional and kinetic asymmetry revealed in proteoliposomes. Biochim Biophys Acta 1828(9):2238–2246
Garaeva AA, Oostergetel GT, Gati C, Guskov A, Paulino C, Slotboom DJ (2018) Cryo-EM structure of the human neutral amino acid transporter ASCT2. Nat Struct Mol Biol 25(6):515–521
Hattab G, Warschawski DE, Moncoq K, Miroux B (2015) Escherichia coli as host for membrane protein structure determination: a global analysis. Sci Rep 5:12097
Indiveri C, Galluccio M, Scalise M, Pochini L (2013) Strategies of bacterial over expression of membrane transporters relevant in human health: the successful case of the three members of OCTN subfamily. Mol Biotechnol 54(2):724–736
Kaur J, Kumar A, Kaur J (2018) Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. Int J Biol Macromol 106:803–822
Kato Y (2020) Extremely low leakage expression systems using dual transcriptional-translational control for toxic protein production. Int J Mol Sci 21(3):705
Mitta M, Fang L, Inouye M (1997) Deletion analysis of cspA of Escherichia coli: requirement of the AT-rich UP element for cspA transcription and the downstream box in the coding region for its cold shock induction. Mol Microbiol 26(2):321–335
Rebsamen M, Pochini L, Stasyk T, de Araujo ME, Galluccio M, Kandasamy RK, Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, Huber KV, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, Huber LA, Superti-Furga G (2015) SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519(7544):477–481
Phue JN, Lee SJ, Trinh L, Shiloach J (2008) Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5alpha). Biotechnol Bioeng 101(4):831–836
Galluccio M, Pingitore P, Scalise M, Indiveri C (2013) Cloning, large scale over-expression in E. coli and purification of the components of the human LAT 1 (SLC7A5) amino acid transporter. Protein J 32(6):442–448
Funding
This work was in part supported by “Fondi di Ateneo” from the Università della Calabria (to CI and MG) and in part by PON (Programma Operativo Nazionale) Project No. 01_00937 granted by MIUR (Ministry of Education, University and Research) Italy to CI.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Galluccio, M., Pantanella, M., Giudice, D. et al. Low temperature bacterial expression of the neutral amino acid transporters SLC1A5 (ASCT2), and SLC6A19 (B0AT1). Mol Biol Rep 47, 7283–7289 (2020). https://doi.org/10.1007/s11033-020-05717-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-020-05717-8